ALDX Aldeyra Therapeutics Inc.

7.81
-0.15  -2%
Previous Close 7.96
Open 8.03
Price To Book 7.51
Market Cap 213958269
Shares 27,395,425
Volume 157,065
Short Ratio
Av. Daily Volume 212,640

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 planned for 2019.
ADX-102
Dry eye syndrome
Phase 3 data due early 2019.
Reproxalap (ADX-102)
Allergic conjunctivitis
Phase 3 data due 2H 2019.
ADX-102
Noninfectious anterior uveitis
Phase 3 initial data due in 2H 2019.
ADX-102
Sjögren-Larsson Syndrome (SLS)
Phase 2 trial to be initiated in 2019.
ADX-1612 (ganetespib)
Mesothelioma
Phase 3 trial to be initiated in 2019 with initial data due 2020.
ADX-2191
Proliferative vitreoretinopathy (PVR)

Latest News

  1. Aldeyra Therapeutics to Host 2019 Research & Development Day
  2. Research Report Identifies Cameco, American Equity Investment Life Holding, AG Mortgage Investment Trust, Arena Pharmaceuticals, Mimecast, and Aldeyra Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  3. Aldeyra Therapeutics Expands Retinal Disease Pipeline with Acquisition of Helio Vision
  4. Aldeyra Therapeutics Announces Promotion of Stephen G. Machatha, Ph.D. to Position of Senior Vice President of Technical Operations
  5. Aldeyra Therapeutics Announces Promotion of David McMullin to Position of Chief Commercial Officer
  6. Edited Transcript of ALDX earnings conference call or presentation 14-Nov-18 1:00pm GMT
  7. Aldeyra Therapeutics Announces Last Patient Dosed in the ALLEVIATE Phase 3 Clinical Trial
  8. Should You Buy Aldeyra Therapeutics Inc (ALDX)?
  9. Should You Be Concerned About Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) Historical Volatility?
  10. Aldeyra Therapeutics to Participate at Citi's 2018 Global Healthcare Conference
  11. Aldeyra Therapeutics Announces Third Quarter 2018 Financial Results
  12. Recent Analysis Shows Freightcar America, Anworth Mortgage Asset, AMN Healthcare Services, Cenovus Energy, Dynex Capital, and Aldeyra Therapeutics Market Influences — Renewed Outlook, Key Drivers of Growth
  13. Aldeyra Therapeutics to Present at the 2018 Stifel Healthcare Conference
  14. Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Third Quarter 2018 Financial Results
  15. Mangrove Partners: Performance, AUM, and Holdings
  16. Aldeyra Therapeutics (ALDX) Looks Good: Stock Adds 7.5% in Session
  17. Aldeyra Therapeutics to Present at the 2018 Cantor Global Healthcare Conference
  18. Aldeyra Therapeutics, Inc. Announces Public Offering of Common Stock
  19. Aldeyra Surges on Positive Dry Eye Study Data on Reproxalap